4 fatty acids might represent the potential sources of acrolein under oxidative stress. On the other hand, Anderson et al. (11) have also shown that acrolein could be formed from a myeloperoxidase (MPO)-catalyzed oxidation of threonine in vitro.
An iron chelate, ferric nitrilotriacetate (Fe 3+ -NTA), is known to be a strong inducer of renal proximal tubular necrosis (12) . It also induces a high incidence of renal adenocarcinoma in rodents after repeated intraperitoneal administration of Fe 3+ -NTA (12) (13) (14) . Oxidative stress has been suggested to play a critical role in the Fe 3+ -NTA-induced acute nephrotoxicity (15), which finally leads to a high incidence of renal adenocarcinoma in rodents (16). In the present study, to verify the formation of acrolein-derived DNA adduct under oxidative stress in vivo, we raised a new type of monoclonal antibody that specifically recognizes an acrolein-derived DNA adduct and examined the formation of this adduct in the Fe 3+ -NTA-induced carcinogenesis model. Furthermore, utilizing MPO-knockout mice, we examined whether the MPO-catalyzed oxidation system was involved in the production of acrolein in this experimental animal carcinogenesis model. The elution profiles were monitored by absorbance at 370 nm.
Reaction of 2'-deoxynucleosides with acrolein. 2'-Deoxynucleosides (2 mM) were
incubated with acrolein (10 mM) in 0.1 M sodium phosphate buffer (pH 7.4) for 24 h.
Identification of an antigenic acrolein-2'deoxyadenosine adduct. The reaction mixture (100 ml) of 2'-deoxyadenosine (2 mM) and acrolein (10 mM) was injected and fractionated (every one minute) with a reverse-phase HPLC using a Develosil ODS-HG-5 column (4. Reaction of calf thymus DNA with aldehydes. Calf thymus DNA (1 mg/ml) was mixed with aldehydes (10 mM) and incubated in phosphate buffer (pH 7.4) at 37°C for 24 h. The reaction was stopped by ethanol precipitation, and the precipitated DNA was washed with cold 70% ethanol. The amount of the DNA was determined by measuring the fluorescence intensity (ex, 415 nm/em, 505 nm) formed by the reaction of the 2'-deoxyribose moiety with 3,5-diaminobenzoic acid.
Preparation of a monoclonal antibody against acrolein-modified DNA. The acroleintreated calf thymus DNA (0.5 mg/ml) was electrostatically complexed with an equal volume of methylated BSA (0.5 mg/ml) (17). The complex was emulsified with an equal volume of complete Freund's adjuvant. Six-week-old female Balb/c mice were intraperitoneally immunized with this emulsion (100 ml). After 2 weeks, the mice were boosted with the acrolein-treated DNA/methylated BSA emulsified with an equal volume of incomplete 8
ELISA.
The indirect noncompetitive ELISA procedure has been previously described (18). Briefly, 100 ml of antigens in PBS were coated in wells and kept at 4°C overnight. After washing and blocking with 4% Block Ace (Dainihon Seiyaku, Osaka, Japan), 100 ml of the mAb21 (1/100 dilution) in PBS containing 0.05% Tween-20 (TPBS) was then added, and the wells were incubated at 37°C for 2 h. After washing, 100 ml of anti-mouse IgG goat antibody peroxidase labeled (1/5000 in TPBS) was added, and the wells were incubated at 37°C for 1 h.
After washing, 100 ml of o-phenylenediamine solution (0.5 mg/ml containing 0.03% H 2 O 2 in citrate-phosphate buffer) was added. The color developing reaction was stopped by the addition of 50 ml of 2 N H 2 SO 4 . The binding of the antibody to the antigen was evaluated by measuring the absorbance at 492 nm.
Competitive indirect ELISA was performed for estimating the cross-reactivity of the low-molecular-weight compounds with the antibody. The acrolein-modified calf thymus DNA (0.05 mg/well) was used as the coating antigen. For the competitive reaction, 50 ml of competitors in PBS was mixed with an equal volume of the antibody (1/100 dilution) in PBS containing 4% BSA. The competitor solution was kept at 4°C overnight, and 90 ml of the mixture was used as the primary antibody. The cross-reactivity of the antibody to the competitors was expressed as B/B 0 , where B is the amount of mAb21 bound to the coating antigen in the presence of the competitor and B 0 is in the absence of a competitor.
Immunocytochemical detection of acrolein adducts.
(i) Acrolein-2'-deoxyadenosine adduct. Cells were fixed overnight in PBS containing 2% paraformaldehyde and 0.2% picric acid at 4°C. Membranes were permeabilized by exposing the fixed cells to PBS containing 0.3% Triton X-100. To eliminate the binding of the antibody to the RNA containing acrolein-adenosine adduct, coverslips were treated with 100 mg/ml ribonuclease A (Qiagen, Tokyo, Japan) in TEN buffer (10 mM Tris-HCl, pH 7.4, and 1 mM ethylenediaminetetraacetic acid (EDTA), pH 7.6, 400 mM NaCl) for 60 min at 37°C.
Coverslips were then washed once in PBS and incubated with 10 mg/ml proteinase K (Wako) in 100 mM Tris-HCl, pH 7.5, and 10 mM EDTA for 10 min at room temperature. To provide maximal exposure of mAb21 to regions of DNA where acrolein-2'-deoxyadenosine lesions may exist, the DNA was denatured at room temperature with 2 M HCl for 5 min and then neutralized with 2.5 volumes of 1 M Tris-base. To prevent nonspecific antibody binding, the coverslips were washed two times in PBS and blocked for 1 h at room temperature with 5%
BSA in TPBS. The cells were then incubated in primary antibody (mAb21) at 4°C overnight.
The cells were then incubated for 1 h in the presence of fluorescein isothiocyanate (FITC)-labeled anti-mouse IgG (Dako Japan Co., Ltd., Kyoto, Japan), rinsed with PBS containing 0.3% Triton X-100, and were mounted on glass slides using 50% glycerol in PBS. Images of cellular immunofluorescence were acquired using a Zeiss LSM5 PASCAL confocal laser scanning microscope with a x 40 objective (488-nm excitation and 518-nm emission). The DNA was stained with propidium iodide, while damage was co-localized using a FITClabeled secondary antibody.
(ii) Acrolein-lysine adduct. Cells were fixed overnight in PBS containing 2% paraformaldehyde and 0.2% picric acid at 4°C. Membranes were permeabilized by exposing the fixed cells to PBS containing 0.3% Triton X-100. The cells were then sequentially incubated in PBS solutions containing blocking serum (5% normal goat serum) and immunostained with anti-protein-bound acrolein monoclonal antibody 5F6 (mAb5F6) (10).
The cells were then incubated for 1 h in the presence of FITC-labeled anti-mouse IgG (Dako Japan Co., Ltd., Kyoto, Japan), rinsed with PBS containing 0.3% Triton X-100, and were mounted on glass slides using 50% glycerol in PBS. Images of cellular immunofluorescence were acquired using a Zeiss LSM5 PASCAL confocal laser scanning microscope with a x 40 objective (488-nm excitation and 518-nm emission). DNA was stained with propidium iodide, while damage was co-localized using a FITC-labeled secondary antibody. Briefly, after deparaffinization with xylene and ethanol, normal rabbit serum (Dako; diluted to 1:75) for the inhibition of the nonspecific binding of the secondary antibody, a primary antibody (0.5 mg/ml), biotin-labeled rabbit anti-mouse IgG serum (Vector Laboratories; diluted to 1:300), and avidin-biotin complex (Vector; diluted to 1:100) were sequentially used.
Procedures, using PBS or the IgG fraction (0.5 mg/ml) of normal mouse serum instead of mAb21, showed no or negligible positive responses. Preparation of a monoclonal antibody against acrolein-modified DNA. It has been suggested that acrolein modification of DNA may contribute to so-called spontaneous mutagenesis, thereby playing a role in aging and cancer. Hence, to examine whether acrolein endogenously generated under oxidative stress is involved in the formation of acrolein-DNA adduct, we attempted to detect the acrolein-modified DNA by an immunochemical procedure.
RESULTS

Formation
To raise a monoclonal antibody specific to acrolein-modified DNA, mice were immunized with the acrolein-modified calf thymus DNA, and after the fusion, the hybridomas were selected by the reactivities of the culture supernatant to the immunogen. We finally obtained one clone (clone No. 21), which exhibited the most distinctive recognition of the acroleinmodified DNA over native DNA ( Fig. 2A ). As shown in Fig. 2B , incubation of calf thymus DNA (1 mg/ml) with 10 mM acrolein resulted in a time-dependent increase in immunoreactivity with the monoclonal antibody 21 (mAb21). In spite of an extensive screening of hybridomas, which produce monoclonal antibodies specific to the acroleinmodified DNA, it is still conceivable that the antibody recognizes epitopes originating from other reactive aldehydes. Hence, we examined the immunoreactivity of the antibody to aldehyde-treated DNA by a direct ELISA and found that, among the aldehydes tested, acrolein was the only source of immunoreactive structures generated in the DNA (Fig. 2C ). It is notable that the antibody scarcely reacted with the DNA treated with an acrolein analog, crotonaldehyde. In addition, the binding of the acrolein-modified DNA to mAb21 was scarcely inhibited by the reaction mixtures of acrolein/2'-deoxyguanosine, acrolein/2'-deoxythymidine, and acrolein/2'-deoxycytidine, but most significantly inhibited by the reaction mixture of acrolein/2'-deoxyadenosine ( Fig. 2D ). In addition, to attest the selectivity observed for free acrolein-nucleoside adducts is identical with the situation in double-stranded DNA, we examined the immunoreactivity of the acrolein-modified oligonucleoside 50 mers (dA 50 , dG 50 , and dC 50 ) by a direct ELISA and found that the antibody reacted only with the acroleinmodified dA 50 ( Fig. S2 ). These data strongly suggest that mAb21 selectively recognizes an acrolein-2'-deoxyadenosine adduct as the major epitope.
Identification of an antigenic acrolein-2'-deoxyadenosine adduct. To identify an acrolein-2'-deoxyadenosine adduct recognized by mAb21, the immunoreactivity with the reaction products of acrolein with 2'-deoxyadenosine was characterized. As shown in Fig. 3A , the ELISA analysis of the HPLC fractions for immunoreactivity with mAb21 showed that the antibody had immunoreactivity with only one fraction (product a) eluted at 4 min. The structure of the antigenic product a was characterized by LC-MS, UV, and 1 H-and 13 C-NMR.
the major products, but they scarcely inhibited the binding of the acrolein-modified DNA to mAb21 (Fig. S3 ). These data suggest that the acrolein-2'-deoxyadenosine adduct (1,N 6 -propano-2'-deoxyadenosine) is an intrinsic epitope of mAb21.
Formation of acrolein-2'-deoxyadenosine adduct in rat liver epithelial RL34 cells exposed to acrolein. It is known that acrolein is extremely toxic to living cells (4) . As shown in Fig. 4A , the treatment of rat liver epithelial RL34 cells with acrolein resulted in dose-and time-dependent decrease in MTT reduction levels. Essentially all cells were detached from culture dishes within 8 h at a dose of 50 mM acrolein (data not shown). The acrolein-mediated cell death was accompanied by marked changes in cellular morphology, most notably the swelling of the cells, which changes were evident in phase contrast microscopy. It was anticipated that the cytotoxicity of acrolein was due to its facile reactivity toward cellular macromolecules, including protein and DNA. To examine the correlation between cytotoxicity and the generation of these acrolein-derived adducts, we tested whether the acrolein-2'-deoxyadenosine adduct was formed in cultured cells in vitro. As shown in Fig. 4B , when the cells were exposed to acrolein (50 mM) for 1 h, immunoreactivity with mAb21 was mainly observed in the nuclei. In addition, we also observed that acrolein generated the epitopes recognized by an antibody (mAb5F6) raised against acrolein-modified protein (Fig. 4C) . Thus, the acrolein modification of the protein and DNA seems to be closely associated with the cytotoxicity of acrolein. Meanwhile, we have also observed that acrolein induces depletion of glutathione and activation of mitogen-activated protein kinases, such as c-Jun N-terminal kinases and p38, in RL34 cells (Kawai, Y., Hachisuka, S., and Uchida, K., unpublished monoclonal antibodies against the acrolein-lysine adduct (mAb5F6) and 8-oxo-2'-deoxyguanosine (mAbN45.1) were also used for comparison. It has been shown that iron overload using Fe these and the observation that the acrolein-derived adducts co-localized with 8-oxo-2'-deoxyguanosine, a marker of oxidative stress, strongly suggest that acrolein was generated under oxidative stress.
MPO-catalyzed oxidation of threonine as an alternative source of acrolein. On the other hand, it has been demonstrated that acrolein is also generated from the MPO-catalyzed oxidation of an amino acid (threonine) in vitro (11) . In addition, MPO appeared to catalyze lipid peroxidation (25) . These and the observations that neutrophil and macrophage infiltration is present in the kidney of Fe
3+
-NTA-treated rats (Toyokuni, S., unpublished observation)
suggest that MPO might play a potential role in the generation of acrolein in this iron-induced carcinogenesis model. Consistent with the previous findings, acrolein was detected in the MPO-catalyzed oxidation of threonine as the major product (Fig. 7A) . A maximal generation of acrolein was observed at 6 h followed by a gradual decline to 24 h was observed in the MPO-H 2 O 2 -Cl -system. This transient accumulation of acrolein in the MPO-catalysed threonine oxidation system was attested to be due to the secondary reaction of the primary product (acrolein) to the substrate (threonine) present in the reaction mixture (data not shown).
These data supported the previous findings that MPO-catalyzed threonine oxidation could be a These data provide direct evidence that MPO is not essential for the generation of acrolein, at least, in this experimental model of carcinogenesis.
DISCUSSION
The previous observations that the metal-catalyzed oxidation of low-density lipoprotein is associated with the formation of the apo B-bound acrolein suggested that substantial amounts of acrolein might be generated during the peroxidation of polyunsaturated fatty acids (6) . In the present study, we also observed that the peroxidation of polyunsaturated fatty acids with an iron/ascorbate-mediated free radical-generating system produces multiple products that react with DNPH, as monitored by reverse-phase HPLC, and one of the products comigrates with the DNPH derivative of authentic acrolein (Fig. 1) . These data strongly suggest that the peroxidation of polyunsaturated fatty acids represents a potential endogenous pathway for the production of acrolein. Although the mechanism for the formation of acrolein during lipid peroxidation has not yet been experimentally resolved, it is not unlikely that acrolein represents a major causal factor that contributes to the development of tissue damage under oxidative stress.
Among all the a,b-unsaturated aldehydes, acrolein exhibits the greatest reactivity with nucleophiles, such as proteins (5) . Upon reaction with protein, acrolein selectively reacts with the sidechains of the cysteine, histidine, and lysine residues. Of these, lysine generates the most stable product. The b-substituted propanals and Schiff's base crosslinks had been suggested as the predominant adduct; however, the major adduct formed upon the reaction of acrolein with protein was identified as a novel lysine product, FDP-lysine, which requires the attachment of two acrolein molecules to one lysine side chain (6) . In addition, we have recently shown that the FDP-lysine adduct generated in the acrolein-modified protein represents a thiol-reactive electrophile (26). The formation of a similar FDP-type adduct (dimethyl-FDP-lysine) has been reported in the lysine modification with the acrolein analogue, crotonaldehyde (23) . In our previous study, we obtained a murine monoclonal antibody, mAb5F6, that clearly distinguished the acrolein-modified BSA and oxidized LDL from native BSA and LDL and showed that it recognized the acrolein-lysine adduct (FDP-lysine) as the major epitope (6) . Using this antibody, it was clearly demonstrated that atherosclerotic lesions contained antigenic materials in the granular cytoplasmic elements of foam cells and the thickening neointima of arterial walls (6) . In addition, the presence of antigenic materials has also been observed in the nigral neurons of patients with Parkinson's disease (27) , in which oxidative stress and mitochondrial respiratory failure with a resultant energy crisis have been implicated as two major contributors to nigral neuronal death.
It has been shown that, upon reaction with DNA, acrolein primarily reacts with 2'-deoxyguanosine and forms the 1,N 2 -propano-2'-deoxyguanosine adduct (28) (29) (30) . In later studies, the 1,N 2 -propano-2'-deoxyguanosine adduct was detected in the DNA extracted from rat and human liver (31-33) and from lymphocyte DNA in patients undergoing treatment with cyclophosphamide, a precursor of acrolein (34, 35) . It is striking to note that the acroleinderived 2'-deoxyguanosine adducts are mutagenic in vitro and in vivo (36, 37) . This may be correlated to our previous findings that the acrolein adduct (FDP-lysine) was markedly generated in the livers of rats exposed to the carcinogenic chemicals, such as butylated hydroxyanisole, 4-dimethylaminoazobenzene, and 2-acetylaminofluorene (38) . In addition, we approach has been taken in this study. Immunologic detection is a powerful tool that can be used to evaluate the presence of a desired target and its subcellular localization. A major advantage of this technique over biochemical approaches is the evaluation of small numbers of cells or archival tissues that may otherwise not be subject to analysis. We successfully raised a murine monoclonal antibody, mAb21, which clearly distinguished the acrolein-modified DNA from the native DNA. This antibody appeared to be highly specific for the acrolein-modified DNA and did not cross-react with other aldehyde-modified DNA (Fig. 2) . In addition, we identified the 1,N 6 -propano-2'-deoxyadenosine as the major epitope of mAb21 (Fig. 3) . Using this antibody, we demonstrated the formation of the acrolein-2'-deoxyadenosine adduct in rat liver epithelial RL34 cells exposed to acrolein (Fig. 4) . Furthermore, the in vivo study demonstrated that the Fe
3+
-NTA treatment resulted in a significant accumulation of the acrolein adduct in the nuclei of the proximal tubular cells, the target cells of this carcinogenesis model (Fig. 5) . The same cells were also stained with an alternative mAb5F6 that recognizes an acrolein-lysine adduct (FDP-lysine), by which cytosolic accumulation of acrolein-modified proteins appeared (Fig. 6 ). As far as we know, this is the first report that immunohistochemically proved the in vivo formation of acrolein-derived DNA adducts in the target organ of the carcinogenic protocol.
On the other hand, it has been suggested that MPO in the presence of H 2 O 2 and Cl -is an alternative source of acrolein in vivo (11) . MPO is an enzyme found mainly in neutrophils and to a lesser degree in monocytes (42) . In chemoattractant-activated neutrophils, MPO transforms H 2 O 2 generated during the oxidative burst into highly cytotoxic hypochlorous acid (HOCl) in the presence of chloride ions (43) . This MPO-H 2 O 2 -Clin the killing of microbes by neutrophils (19, 44) . It may also be involved in their cytotoxicity against tumor cells (45, 46) and in the tissue damage at sites of inflammation where neutrophils can release both MPO and H 2 O 2 (47) (48) (49) (50) . It has been proposed that the pathway for acrolein synthesis involves the initial chlorination of the a-amino group of threonine by HOCl (11) . In the absence of the enzymatic system, HOCl alone could convert threonine into acrolein, strongly implicating HOCl in the MPO-H 2 O 2 -Cl -system (11). We have also examined the generation of acrolein in the threonine oxidation and observed that, in contrast to the peroxidation of polyunsaturated fatty acids, the MPO-H 2 O 2 -Cl -system transiently generated acrolein, which was proven to be due to the secondary reaction of the product (acrolein) with the catalyst (MPO) and/or the substrate (threonine) present in the reaction mixture (Fig. 7) .
Thus, although non-enzymatic lipid peroxidation and MPO-catalyzed threonine oxidation showed considerably distinct profiles in kinetics, these data supported the previous findings (Fig. 8B) . These data provide direct evidence that MPO is not essential for the generation of acrolein, at least, in this experimental model of renal carcinogenesis.
In summary, to verify the acrolein generation under oxidative stress in vivo, we raised a new type of monoclonal antibody (mAb21) against the acrolein-modified DNA and found that the antibody most significantly recognized the 1,N 6 -propano-2'-deoxyadenosine adduct. The fomation of this adduct was attesto ted in rat liver epithelial RL34 cells exposed to acrolein and in rats exposed to ferric nitrilotriacetate (Fe 3+ -NTA), a carcinogenic iron chelate that specifically induces oxidative stress in the kidney of rodents. These data suggest that the formation of a carcinogenic aldehyde during lipid peroxidation may be causally involved in the pathophysiological effects associated with oxidative stress. dG 50 , and dC 50 ) (0.5 mg/ml) with 5 mM acrolein in phosphate buffer (pH 7.4) at 37°C
for 24 h. Symbols: , dA 50 ; , dG 50 ; , dC 50 ; , acrolein-dA 50 ; , acrolein-dG 50 ; , acrolein-dC 50 . , acrolein-2'-deoxyadenosine (propano-dA); , acrolein-2'-deoxycytidine (propano-dC); , acrolein-2'-deoxyguanosine (propano-dG).
